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Abstract 
Aims: 
To evaluate the relationships between immunohistochemical markers related to cellular 
senescence, cell proliferation and histological grade of epithelial dysplasia of the oral cavity (OD). 
In addition, the predictive value of these markers for progression of OD was assessed. 
Methods: 
Retrospective immunohistochemical analyses were performed on 86 formalin fixed and 
SDUDIILQHPEHGGHGVSHFLPHQVRI2'DQGRUDOVTXDPRXVFHOOFDUFLQRPD26&&IRU.LȖ+$;
p53, p16, H3K9me3 and CycD1. Three separate areas representing the highest severity of OD on 
each slide were digitally annotated by two independent pathologists. Mean automated histoscores 
of the selected markers were generated and compared to that of age-matched healthy controls 
(n=24). Follow-up data of OD was retrieved and anonymised by a clinical team member and linked 
using unique participant identifiers. The median follow-up was 10.9 years (interquartile range: 10.1-
11.5). 
Results: 
.LSȖ+$;S DQGSS ZHUHVLJQLILFDQWO\LQFUHDVHGZLWKKLJKHU
KLVWRORJLFDO JUDGH RI 2' Ȗ+$; S  EXW QRW KLVWRORJLFDO JUDGH RI 2' S  ZDV
prospectively associated with disease progression. Using the median histoscorH IRU Ȗ+$;
(median histoscore = 17) as a cut-RII KLVWRVFRUH ZDV DVVRFLDWHG ZLWK DQ LQFUHDVHG ULVN RI
disease progression (HR=3.15, 95%CI 1.41-7.39, p=0.0064). 
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Conclusions: 
Although proliferation marker Ki67, DNA damage/checkpoint PDUNHUVȖ+$;DQGS53 were 
increased in higKHU JUDGH RI 2' RQO\ Ȗ+$; ZDV predictive of disease progression. These 
observations may reflect the role of DNA replicative stress in the transformation from OD to OSCC. 
/DUJHUVWXGLHVVKRXOGHYDOXDWHZKHWKHUȖ+$;FDQEHXVHGDVa predictive marker of OD. 
 
Keywords: oral cavity, neoplasm, carcinoma in situ, cellular senescence, biomarkers, 
immunohistochemistry 
 
Introduction 
Although oral cancer accounts for only 3% of all cancer cases, its worldwide incidence has 
increased in recent years.1 This increase has been associated with human papillomavirus 
infection, particularly the high-risk HPV-16 subtype, in cancers of the oropharynx.2 Oral epithelial 
dysplasia (OD) is a known premalignant condition associated with oral squamous cell carcinoma 
(OSCC). Clinically, OD lesions appear as white or red patches (leukoplakia and erythroplakia 
respectively) occurring anywhere on the mucosal surfaces of the mouth. 
 Although histological assessment is the gold standard for diagnosis and the grade of OD is 
a key risk factor of malignant transformation, its assessment is subjective with substantial inter-
observer variability.3, 4 Moreover, the majority of OD lesions do not progress to cancer: reported 
progression rates ranged between 6% and 36%.5, 6 
 
Although significant efforts have been made to improve the predictive value of histological 
grading, e.g. by combining DNA ploidy analysis with OD grading,7 accurate positive predictive 
markers of progression do not exist.8, 9 The mainstay treatment for OD remains regular surveillance 
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and surgical resection,10 and patients with recurrence (10-20% of those with OD) may require 
multiple operations in an anatomically confined and complex region with significant impact on 
quality of life.  Hence, improved understanding of the molecular mechanisms underlying the 
progression from OD to OSCC could help stratify risks of patients with OD and streamline their 
follow-up, with the potential to identify malignant transformation early, while minimising morbidity 
from active surveillance and repeat resections.11 
Key proteins in cell cycle and proliferation control have been evaluated as candidate 
biomarkers to predict progression in OD, with limited success.12 Senescence is an irreversible form 
of growth arrest and, once it is established, cells are unable to express genes required for 
proliferation even when exposed to mitogenic growth factors. Hence, senescence is a potent 
mechanism of tumour suppression, associated with human and mouse benign neoplastic 
lesions.11, 13 Senescent cells continue to remain metabolically active with characteristic large 
flattened morphology (at least in vitro), and also display characteristic changes in gene 
expression.14 At the molecular level, replicative senescence of human cells is triggered by telomere 
attrition, which is registered by the cell as DNA damage and results in the activation of the tumour 
suppressor gene TP53. During replicative senescence, the CDK inhibitor p16INK4a accumulates 
in the cell, inhibiting the CDK-mediated phosphorylation of pRB and contributing to cell cycle 
arrest.  These two pathways are essential for senescence activation in human cells, and 
alterations of these pathways have been reported in large cohorts of OSCC and OD.15 In addition, 
senescence can be triggered by the presence of an activated oncogene in an otherwise normal 
cell.13  
This study aimed to evaluate whether the expression of markers related to cellular 
senescence was altered in OD, compared to normal oral epithelium. In addition, the predictive 
potential of these markers was explored.   
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Materials and methods 
Ethical approval 
 This study was approved by the local ethics committee of the West of Scotland on 3 
December 2010 (REC reference number: 10/S0704/56). 
 
Patient selection and follow-up data 
Pathological archival specimen 
Anonymised surplus formalin fixed and paraffin embedded (FFPE) specimens of OD and 
OSCC were retrospectively identified and retrieved from the NHS Greater Glasgow and Clyde 
Biorepository by a pathologist (DM). Follow-up data of OD was retrieved and anonymised by a 
member of the clinical team (NS) using unique participant identifiers. 
 
Age-matched normal control samples 
Age-matched healthy volunteers were identified at the head and neck surgical outpatient 
clinic of the Queen Elizabeth University Hospital (Glasgow, the United Kingdom) by a consultant 
surgeon (JDM) who provided routine care of the volunteers. Study participation was voluntary and 
written informed consent was obtained from each volunteer. 
 
Biopsy procedure for healthy age-matched volunteers 
A single 4mm disc of normal oral mucosa was obtained from each volunteer using a punch 
biopsy device after infiltration of a local anaesthetic. Standard antiseptic technique was followed. 
All biopsy specimens were fixed in neutral buffered formalin and embedded in paraffin before 
immunohistochemical staining. 
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Immunohistochemistry  
Histology slides were stained for markers of proliferation (Ki67, CycD1), DNA 
damage/checkpoint markers (JH2AX), cellular senescence (p53 and p16), chromatin structure 
(trimethyl-Histone H3 (Lys9) [H3K9me3]) and negative control (IgG) according to established 
protocols of the Histological Services at the Cancer Research UK Beatson Institute, with 
appropriate positive and negative controls. All staining was done on a Dako Autostainer Link48 
autostainer (Dako, Cambridge UK). 
The following staining conditions and antibodies were used in this study: Ki67 (RM-9106, 
Thermo Scientific, Clone SP6) at 1 in 200; Ȗ+$;, Cell Signaling, Clone 20E3) at 1 in 50; 
p53 (M7001, Novacastral, Clone DO7) at 1 in 1000; p16 (725-4713, Roche, Clone E6H4) was 
used as received, H3K9me3 (07-442, Millipore, polyclonal) at 1 in 300; CycD1 (M3635, Dako, 
Clone SP4) at 1 in 50; M7023 (negative control, Sigma-Aldrich, polyclonal) at 1 in 9000. Apart from 
p16 and CycD1 staining, all staining was performed after heat-induced epitope retrieval in citrate 
buffer at pH6. For p16 and CycD1 staining, antigen retrieval was performed in Tris-EDTA at pH9 
and EDTA pH 8, respectively. 
 
Interpretation of immunohistochemical assays 
Stained slides were digitised (Hamamatsu NanoZoomer NDP, Hamamatsu Photonics, 
Welwyn Garden City, UK), reviewed and analysed using Slidepath Digital Image Hub V4.0.7 (Leica 
Microsystems, Milton Keynes, UK).  
Histological grade of OD and qualitative assessments of the histology slides were 
performed by two collaborating pathologists (KH and CEM), who were blinded to the histological 
grade of the original diagnostic report at the time of their assessments. As discrete areas of OD 
often develop within a background of normal tissue, three separate areas representing the highest 
severity of OD on each slide were digitally annotated based on hematoxylin and eosin stained 
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specimen slides before the assessment of other immunohistochemical markers. For specimens 
from normal healthy controls, three random areas of normal epithelium were annotated. 
Automated +LVWRVFRUHV >(?î  QHJDWLYH FHOOV(?(?(?î  ZHDNO\ VWDLQHG FHOOV(?(?(?î % 
modHUDWHO\ VWDLQHG FHOOV(?(?(?î % strongly stained cells] of the annotated areas were then 
generated by digital image analysis. Mean values of the histoscores generated from the three 
separate areas of each slides were used for statistical analysis of the immunohistochemical 
markers assessed. Each histoscore has a range of possible scores between 0 and 300. The 
algorithms used were unable to generate histoscores for <5% of samples. 
 
Human papillomavirus (HPV) status 
The HPV status of p16-positive specimens was evaluated by HPV 16/18 polymerase chain 
reaction (PCR) at the Queen Elizabeth University Hospital (Glasgow, the United Kingdom) 
according to established protocol. 
 
Statistical analysis 
Statistical tests were performed using Prism 6 (GraphPad software, San Diego, CA, US). 
Differences between groups were analysed using Kruskal-Wallis and Mann-Whitney U tests, as 
the data were not normally distributed. Significance was considered with a p-value below 0.05. The 
level of statistical significance is indicated using asterisks (*p<0.05 and ****p<0.0001). When 
appropriate, data were presented as median and interquartile range (IQR). Survival analysis was 
performed using Log-rank test; hazard ratio (HR) and 95% confidence interval (95%CI) were 
presented in addition to p-value.  
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Results 
The relationships between grade of disease and biomarkers assessed 
 For the archival specimens (n=86), only age and histological grade at diagnosis were 
available. The median age of diagnosis was 64.6 years old (interquartile range: 53.9-71.5). 
Twenty-four (27.9%) of these archival specimens had mild OD, 17 (19.8%) had moderate OD, 32 
(37.2%) had severe OD and 13 (15.1%) had OSCC. Automated histoscores of the assessed 
immunohistochemical markers were compared by grade of disease, compared to 24 normal age-
matched controls (Table 1, Figure 1 and supplementary Figure 1). With respect to p16 expression, 
seven of the 32 severe OD specimens (21.9%) expressed a high level of p16. Given the known 
link between HPV status and p16, their HPV status was evaluated. Five were HPV positive 
(71.4%, all HPV-16 positive), one was negative (14.3%) and one had too little remaining DNA for 
assessment (14.3%). 
More significantly, the expression of Ki67 (p<0.0001), JH2AX (p=0.03) and p53 (p=0.04) 
was significantly increased with higher histological grade of OD. The expression of these 
biomarkers plateaued or reversed in OSCC. 
 
The relationships between biomarkers assessed and disease progression 
 The median follow-up was 10.9 years (IQR: 10.1-11.5). Of the 73 patients with OD, 18 
improved and were discharged from follow-up (24.7%), 4 progressed to higher grade of dysplasia 
(5.6%) and 19 progressed to develop malignancies (26.0%). For the 23 patients with disease 
progression, the median time to progression was 6.0 years (IQR: 4-6.9). There was no difference 
in the rate of progression by grade of dysplasia (supplementary figure 2, p=0.73). 
 The relationships between assessed biomarkers and disease progression in patients with 
OD were evaluated (Table 2). Two of the 7 patients with a high level of p16 (28.6%) progressed to 
develop OSCC, of whom only one had confirmed HPV infection. Most interestingly, increased 
JH2AX was associated with disease progression (Table 2, p=0.03). Using the median histoscore 
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for JH2AX (median histoscore = 17) as a cut-RIIKLVWRVFRUHZDVDVVRFLDWHGZLWKDQLQFUHDVHG
risk of disease progression (Figure 2; HR=3.15, 95%CI 1.41-7.39, p=0.0064). 
 
Discussion 
Main findings, strengths and limitations 
+LJKHUKLVWRORJLFDOJUDGHVRI2'ZHUHVLJQLILFDQWO\DVVRFLDWHGZLWKLQFUHDVHG.LȖ+$;
and p53, and subsequently plateaued or reversed in patients with malignancy, similar to changes 
REVHUYHGLQSDWLHQWVZLWK%DUUHWW¶VRHVRSKDJXV.16 Moreover, JH2AX, which predictive value has not 
been thoroughly evaluated6, was associated with disease progression. 
Although p16 expression is an established marker of senescence, infection with HPV 
upregulates expression of non-functional p16 due to the loss of pRB function, which is unlikely to 
be associated with senescence. Indeed, in patients with severe OD, the majority of specimens with 
high p16 expression had confirmed HPV infection. Consistent with previous reports that only a 
small proportion of patients with OSCC (<5%) were infected with HPV17 and that p16 was a poor 
predictive marker of OD8, 18, p16 was not associated with increasing histological grade of OD nor 
progression in this cohort. Other novel senescence markers assessed in this study did not show 
significant changes in expression by grade of OD or progression status.  
This study is one of the few studies reported to date that included a normal age-matched 
control group.8, 19 This highlights the feasibility of establishing a cohort of normal healthy control, 
which is important for the development of clinically relevant biomarkers.20 In addition, this study 
also procured sufficiently long follow-up, and the rate of progression to malignancy was similar to 
that in previously reported studies (26%).5, 6 However, the number of participants included in this 
exploratory study was small. It had limited power to detect small changes in the expression of the 
biomarkers assessed. Moreover, multiple comparisons could increase the probability of type I 
errors. Therefore, larger studies would be required to validate the associations observed. 
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Recommendations for future studies 
 The expression of proliferation markers Ki67, DNA damage/checkpoint markers JH2AX and 
p53 was significantly higher with increasing grades of OD, which may aid the determination of 
histological grade of OD. The significance of the observed patterns of expression of Ki67, JH2AX in 
and p53 in OSCC is unclear. Including normal controls in future biomarker studies will help confirm 
the patterns observed.    
While grade of dysplasia did not predict progression in this cohort of patients, JH2AX 
overexpression was significantly associated with disease progression, with p53 showing a similar 
trend. It was previously proposed that DNA replication stress, consistent with JH2AX 
overexpression observed, may promote genomic instability that may encourage progression from 
OD to OSCC.21 Future studies could further evaluate whether the combination of these two 
common immunohistochemical markers, JH2AX and p53, may better predict the progression of 
OD. 
 
Conclusion 
 Although proliferation markers Ki67, DNA damage/checkpoint markers JH2AX and p53 
were increased in higher grade of OD, only JH2AX was associated with disease progression, 
which may indicate the potential of DNA replicative stress in the transformation from OD to OSCC. 
Larger studies could evaluate whether JH2AX could be used as a predictive marker of OD. 
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Table 1: Automated histoscores by grade of disease, compared to normal healthy control (n=110). 
 
 Normal Mild OC Moderate OC Severe OC OSCC p-value 
Ki67 58.3 (47.2-69.5) 56.5 (45.1-74.1) 78.0 (47.0-105.2) 94.3 (82.3-121.0) 71.3 (40.0-110.0) <0.0001 
Ȗ+$; 11.3 (7.7-19.2) 13.8 (8.5-17.9) 16.0 (7.7-41.4) 25.5 (11.3-62.3) 27.0 (4.0-46.2) 0.03 
p53 13.5 (4.4-22.2) 37.9 (12.7-43.7) 39.7 (14.4-95.3) 17.7 (3.0-111.3) 19.0 (2.3-75.5) 0.04 
p16 0 (0-1.0) 0.3 (0-2.8) 0 (0-1.0) 0 (0-5.0) 0 (0-0.7) 0.59 
H3K9me3 74.0 (58.3-95.1) 76.5 (56.6-111.3) 77.7 (17.5-105.9) 66.2 (36.1-108.2) 63.3 (39.3-94.0) 0.68 
CycD1 31.5 (16.9-67.5) 23.5 (8.3-51.3) 29.0 (9.5- 71.8) 42.2 (8.9-76.8) 56.3 (30.4-82.9) 0.19 
M7023 
(Negative control) 
0 (0-0.2) 0.3 (0-1.3) 0 (0-0.3) 0.7 (0-1.6) 0 (0-2.5) 0.10 
Data presented as median (IQR) 
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Table 2: Automated histoscores of patients with OD by progression status (n=73). 
 
 
No progression 
n=50 
Progression 
n=23 
p-value 
Ki67 81.0 (47.8-114.7) 83.0 (60.3-101.7) 0.65 
Ȗ+$; 15.3 (8.6-26.9) 25.5 (14.5-56.0) 0.04 
p53 28.9 (7.8-56.3) 69.2 (9.9-95.9) 0.15 
p16 0.2 (0-3.0) 0 (0-0.7) 0.19 
H3K9me3 70 (36.5-105.1) 80 (51.2-112.0) 0.55 
CycD1 28.5 (7.9-58.7) 49.0 (12.7-75.3) 0.11 
M7023 
(Negative control) 
0.3 (0-1.3) 0 (0-0.9) 0.54 
Data presented as median (IQR) 
 
Figure 1: Summary of automated histoscores by grade of disease, compared to normal healthy 
control (n=110).  
 
Figure 2: Kaplan-Meier curve of progression-free survival (PFS) in patients with OD. 
 
Supplementary figure 1: representative images of the immunohistochemical staining by grade of 
disease, compared to normal healthy control (n=110).  
 
Supplementary figure 2: Progression status by grade of OD. 
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